Vistagen Therapeutics, Inc.
VTGN • NASDAQ
Vistagen Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Shawn K. Singh, with a market cap of $22.6M.
CEOShawn K. Singh
Next Earnings
Upcoming earnings announcement for Vistagen Therapeutics, Inc.
Date
Tuesday, June 16, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q4 2026
EPS Estimate
-$0.33
Revenue Estimate
$332.4K
Earnings History
Past 12 earnings reports for Vistagen Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | Q3 2026 | -$0.45Est: -$0.39 | -15.4% | $303.0KEst: $256.5K | +18.1% |  10-Q |
| Nov 13, 2025 | Q2 2026 | -$0.54Est: -$0.47 | -14.9% | $258.0KEst: $339.5K | -24.0% | 10-Q |
| Aug 7, 2025 | Q1 2026 | -$0.47Est: -$0.45 | -4.4% | $244.0KEst: $389.4K | -37.3% | 10-Q |
| Jun 17, 2025 | Q4 2025 | -$0.44Est: -$0.49 | +10.2% | -$15.0KEst: $209.3K | -107.2% | 10-K |
| Feb 13, 2025 | Q3 2025 | -$0.46Est: -$0.52 | +11.5% | $234.0KEst: $179.3K | +30.5% | 10-Q |
| Nov 7, 2024 | Q2 2025 | -$0.42Est: -$0.39 | -7.7% | $183.0KEst: $220.0K | -16.8% | 10-Q |
| Aug 13, 2024 | Q1 2025 | -$0.35Est: -$0.40 | +12.5% | $84.0KEst: $300.0K | -72.0% | 10-Q |
| Jun 11, 2024 | Q4 2024 | -$0.25Est: -$0.37 | +32.4% | $197.3KEst: $410.0K | -51.9% | 10-K |
| Feb 13, 2024 | Q3 2024 | -$0.22Est: -$0.30 | +26.7% | $411.4KEst: $540.0K | -23.8% | 10-Q |
| Nov 9, 2023 | Q2 2024 | -$0.66Est: -$0.68 | +2.9% | $277.7KEst: $180.0K | +54.3% | — |
| Aug 10, 2023 | Q1 2024 | -$0.94 | — | $177.6K | — | 10-Q |
| Jun 28, 2023 | Q4 2023 | -$1.61 | — | $175.6K | — | — |